Skip to content
Sign in
European CDMOs compared · 2026 census

CDMOs in the Netherlands: 8 compared (2026)

8 of the 255 contract development and manufacturing organisations in A4BEE’s European census are headquartered in the Netherlands. None has revenue over €1bn. 1 sit between €250m and €1bn and 7 are smaller or niche.

By ownership: 3 family-owned, 1 private equity, 1 listed, 1 part of a pharma or industrial group and 2 state-owned. The most common capabilities are biologics and biosimilars (5), viral vector and vaccine (5), monoclonal antibody (3), small-molecule API (2) and microbial and protein (2). 7 of the 8 rows rest on audited reports or official company disclosures; the rest come from secondary sources or estimates.

Open these 8 in the interactive mapAll 255 European CDMOs

8 companies

CDMOs in the Netherlands

CompanyHQOwnershipSizeRevenue (as reported)ModalitiesData
Centrient PharmaceuticalsFormerly DSM Sinochem. Enzymatic beta-lactam antibiotics, statins, antifungals; APIs plus finished dosage and CDMO.RijswijkPrivate equityBain CapitalTier 2~€560 mSmall-molecule API, Microbial and proteinhigh
Aspen OssBiochemical/chemical API CDMO: steroid hormones, heparin, peptides, alkaloids. Former Organon/Merck site.OssListedAspen PharmacareTier 3not disclosedSmall-molecule API, Peptidehigh
Batavia BiosciencesBiologics CDMO: viral vaccines/vectors, oncolytic viruses, proteins/antibodies; proprietary yield platforms. Owned by CJ (2021).LeidenPart of a pharma or industrial groupCJ CheilJedangTier 3not disclosedBiologics and biosimilars, Viral vector and vaccine, Monoclonal antibodyhigh
Bilthoven BiologicalsVaccine CDMO (inactivated polio, viral-vector/Vero platforms; also mAbs). Owned by Serum Institute of India.BilthovenFamily-ownedSerum Institute of IndiaTier 3not disclosedViral vector and vaccine, Biologics and biosimilars, Monoclonal antibodyhigh
HALIXMammalian biologics CDMO: viral vectors, vaccines, recombinant proteins (1,000L SUB). Made AstraZeneca's COVID vaccine.LeidenFamily-ownedDroege GroupTier 3not disclosedViral vector and vaccine, Biologics and biosimilars, Monoclonal antibodyhigh
InnoCore PharmaceuticalsDrug-delivery CDMO for long-acting injectables (microspheres, implants, depot gels) via proprietary SynBiosys polymers.GroningenFamily-ownedTier 3not disclosedPeptide, Biologics and biosimilars, Sterile fill-finishhigh
IntravaccVaccine CDMO for infectious-disease/therapeutic vaccines, PoC to Phase I/II. State-owned; sale announced.BilthovenState-ownedDutch StateTier 3not disclosedViral vector and vaccine, Biologics and biosimilars, Microbial and proteinhigh
NecstGenNon-profit cell & gene therapy CDMO and centre of excellence in a purpose-built Leiden GMP facility; genuine third-party CGT manufacturing.LeidenState-ownedTier 3not disclosedCell and gene therapy, Viral vector and vaccinemedium

Size: Tier 1 (revenue over €1bn) · Tier 2 (€250m–€1bn) · Tier 3 (under €250m or niche).

Revenue, staff and site figures are as reported and mix audited accounts with commercial estimates, which are often wrong for private companies. Each row carries a confidence mark; verify a figure before quoting it.

Browse the census

Other European CDMO lists